Thyroid hormone resistance syndrome care technology platforms are the digital infrastructure supporting management of a rare genetic endocrine disorder caused by loss-of-function mutations in thyroid hormone receptor genes that impair cellular sensitivity to thyroid hormone, producing a biochemical paradox identical to the central hyperthyroidism of TSH-secreting pituitary adenoma — elevated or inappropriately normal TSH with elevated free T4 and free T3 — yet arising from a fundamentally different mechanism and requiring a diametrically opposite approach to treatment: the two subtypes of thyroid hormone resistance reflect which receptor isoform is mutated, with RTHβ (resistance to thyroid hormone beta, caused by autosomal dominant mutations in THRB encoding thyroid hormone receptor beta, accounting for more than 3,000 documented cases globally) producing reduced TRβ-mediated effects in the pituitary, liver, heart, and kidneys while preserving TRα-mediated effects in TRα-expressing tissues (heart, bone, gut, brain), creating the clinical paradox of a patient who is biochemically hyperthyroid yet whose pituitary fails to suppress TSH because the pituitary's TRβ-dependent negative feedback is impaired — resulting in elevated TSH driving the thyroid to produce excess T4 and T3 that then acts normally on TRα-expressing tissues (particularly heart, producing tachycardia and palpitations) while TRβ-expressing target tissues remain relatively resistant to these elevated hormone levels, and with RTHα (resistance to thyroid hormone alpha, caused by mutations in THRA encoding thyroid hormone receptor alpha, rarer with fewer than 100 cases globally) producing a completely different clinical phenotype characterized by TRα-mediated tissue hypothyroidism affecting heart, bone, gut, and brain despite normal or near-normal TSH and thyroid hormone levels — with RTHβ clinical features encompassing tachycardia and palpitations from TRα-mediated cardiac sensitivity to elevated T4/T3, attention deficit disorder (ADD/ADHD-like symptoms in TRα-expressing brain regions), goiter from chronic TSH stimulation of thyroid, elevated SHBG from hepatic TRβ resistance, and the critical therapeutic caveat that thyroid ablation, antithyroid drugs, and TSH suppression are CONTRAINDICATED in most RTHβ patients because they target the thyroid gland rather than the receptor defect and can cause profound clinical hypothyroidism in TRβ-resistant tissues while removing the elevated T4/T3 levels that the patient requires to achieve adequate TRβ-mediated function — integrated across RTH biochemical monitoring platforms tracking TSH and thyroid hormone levels with extreme caution regarding over-treatment, cardiac surveillance platforms for tachycardia management, neurodevelopmental assessment platforms for ADD/ADHD monitoring, bone density platforms for skeletal surveillance, genetic documentation platforms for THRB versus THRA variant records, and family screening coordination platforms for the autosomal dominant RTHβ transmission that places 50% of first-degree relatives at risk. When an RTH care platform is unavailable or degraded, endocrinologists cannot access the TSH-free T4 trending that is essential for distinguishing adequate RTHβ biochemistry from harmful over-treatment, cardiologists cannot access the heart rate documentation that drives beta-blocker titration for tachycardia management, and genetic counselors cannot access the variant documentation needed for family cascade screening.
This guide covers what thyroid hormone resistance syndrome care technology platforms need to monitor, why continuous availability matters across TSH and thyroid hormone surveillance, over-treatment risk detection, cardiac monitoring, neurodevelopmental assessment, bone surveillance, and genetic documentation, and how to build a monitoring strategy that protects the multi-specialty digital infrastructure that RTH management requires from initial genetic diagnosis through lifetime clinical monitoring.
Why RTH Care Tech Platforms Cannot Afford Downtime
Thyroid hormone resistance syndrome management creates three platform obligations that are uniquely consequential because the treatment risks in RTH are inverse to virtually all other thyroid disorders.
Over-treatment prevention is the most critical and counterintuitive safety obligation in RTHβ. In primary hyperthyroidism, a TSH of 0.01 mIU/L with elevated free T4 demands antithyroid treatment — but in RTHβ, the same biochemistry represents the patient's compensatory homeostasis, and treating it with antithyroid drugs, radioiodine, or thyroidectomy removes the elevated T4/T3 that TRβ-resistant tissues require to maintain adequate function and produces severe clinical hypothyroidism in tissues that cannot compensate through receptor-mediated mechanisms, making the platform documentation of RTH genetic diagnosis, variant confirmation, and treatment contraindication flagging an active patient safety requirement — because the greatest risk in RTHβ is that a provider unfamiliar with the diagnosis encounters the elevated TSH with high free T4 and initiates antithyroid therapy that is catastrophically harmful in this specific genetic context, and platform downtime that blocks access to the contraindication flag and genetic documentation is a direct patient safety threat.
Cardiac surveillance is the primary symptomatic management obligation in RTHβ. The most disabling symptoms in most RTHβ patients are cardiovascular — resting tachycardia, palpitations, and exercise intolerance driven by normal cardiac TRα sensitivity to the elevated T4/T3 levels that TRβ-resistant tissues require — making heart rate tracking and beta-blocker titration documentation a central management requirement, and making cardiac monitoring platform availability critical for the cardiology co-management that symptomatic tachycardia in RTHβ requires for both quality-of-life management and cardiovascular risk reduction without compromising the thyroid hormone levels that the patient needs.
Genetic variant documentation is a lifetime record safety obligation. RTHβ caused by THRB mutations follows autosomal dominant inheritance, meaning each child of an affected parent has a 50% probability of inheriting the causative variant, and the THRB mutation identified in one family member is the definitive diagnostic reference for cascade genetic screening of all at-risk relatives — a reference that must remain continuously accessible in the platform record across the decades of clinical management and family expansion that RTH families experience, and that cannot be reconstructed if lost due to platform failures, because the specific variant determines genotype-phenotype correlation assessments, reproductive counseling content, and the clinical interpretation framework for all future thyroid function tests in the patient and affected relatives.
What to Monitor on an RTH Care Tech Platform
TSH and Thyroid Hormone Monitoring Platform
The TSH and thyroid hormone monitoring service — integrating baseline TSH, free T4, and free T3 documentation at diagnosis establishing the patient's RTHβ biochemical set-point (the elevated TSH with high-normal to elevated free T4/T3 that represents compensated equilibrium rather than uncontrolled hyperthyroidism), serial TSH and free T4/T3 measurement at 3-6 month intervals for clinical surveillance with the primary goal of detecting over-treatment (falling free T4/T3 with paradoxically "normalizing" TSH that actually indicates clinical hypothyroidism in the RTHβ patient whose tissues require elevated levels), clinical symptom correlation with biochemical values to identify which symptoms reflect TRα-mediated thyroid hormone excess (tachycardia — treatable with beta-blockade) versus TRβ-mediated resistance (goiter, elevated SHBG — intrinsic to the condition), SHBG measurement as a hepatic TRβ-sensitivity marker (elevated in RTHβ reflecting hepatic resistance), reverse T3 measurement where clinically relevant, thyroid antibody testing at diagnosis to exclude autoimmune thyroid disease co-occurrence, thyroid ultrasound scheduling for goiter size monitoring, over-treatment alert flags when free T4/T3 fall below patient-specific set-point despite unchanged dose, treatment holiday documentation when T3 analog (triiodothyroacetic acid — TRIAC) or other experimental therapy is trialed in severely symptomatic patients, and pediatric growth hormone assessment where RTH is diagnosed in childhood with growth concerns — is the primary monitoring target. Check at a 1-minute interval with immediate escalation.
Over-Treatment Risk Monitoring Platform
Monitor the iatrogenic harm prevention service — including antithyroid drug contraindication flag active in patient record and accessible to all treating providers regardless of specialty, radioiodine treatment contraindication documentation with clinical rationale, thyroidectomy contraindication documentation, TSH suppression target contraindication flag (TSH suppression to subnormal levels in RTHβ drives clinical hypothyroidism — unlike in differentiated thyroid cancer management), provider education flag for providers accessing the record outside the managing endocrinology team documenting the RTH diagnosis and treatment contraindications, emergency department alert documentation for presentations where the elevated TSH-high free T4/T3 pattern might prompt antithyroid prescribing by clinicians unfamiliar with RTH, clinical genetics note in medication allergy and alert fields in EHR documenting RTH-specific treatment constraints, missed-diagnosis prevention documentation including the prior diagnostic investigations that ruled out TSHoma (pituitary MRI, alpha-subunit), and telemedicine consultation documentation for second-opinion requests from providers encountering the RTH biochemistry for the first time — at a 1-minute interval.
Cardiac Monitoring Platform
Monitor the cardiovascular surveillance service — including resting heart rate at each visit as the primary symptomatic monitoring parameter for TRα-mediated cardiac sensitivity to elevated thyroid hormone in RTHβ, heart rate trending over time correlated with beta-blocker dose adjustments, 24-hour Holter monitoring scheduling for patients with symptomatic palpitations to characterize arrhythmia burden, exercise heart rate assessment for exercise intolerance evaluation, blood pressure documentation, beta-blocker (usually atenolol or metoprolol — selective beta-1 blockade preferred) dose titration documentation with heart rate response, 12-lead ECG scheduling for patients with suspected arrhythmias, echocardiogram at diagnosis for structural assessment (chronic tachycardia risk of tachycardia-induced cardiomyopathy in severely affected patients), heart rate normalization assessment for patients trialing T3 analog or other TSH-modifying therapy, cardiology co-management referral documentation for complex arrhythmia management, and pediatric cardiac monitoring documentation where RTH is diagnosed in childhood with congenital heart rate concerns — at a 1-minute interval.
Neurodevelopmental Assessment Platform
Monitor the ADHD and neurodevelopmental monitoring service — including ADHD symptom assessment at each pediatric and adult visit using standardized rating scales (Vanderbilt, Conners, ADHD-RS) documenting attention and hyperactivity symptoms driven by TRα-mediated neurological sensitivity to elevated thyroid hormone in RTHβ, cognitive function assessment in RTHα where TRα-mediated neurological hypothyroidism may cause cognitive delay and intellectual disability, learning difficulty documentation and educational accommodation planning, neuropsychological evaluation referral documentation for comprehensive assessment, stimulant medication decision documentation with RTH-specific considerations (stimulant therapy may be appropriate for ADHD symptoms in RTHβ that do not resolve with cardiac symptom control), speech and language assessment in pediatric RTHα patients with developmental delay, school performance monitoring documentation correlated with cardiac and thyroid management adjustments, pediatric neurology co-management referral documentation, behavioral therapy documentation, and transition to adult care planning for pediatric RTH patients with established neurodevelopmental diagnoses — at a 2-minute interval.
Bone Density Monitoring Platform
Monitor the bone density surveillance service — including DEXA scan scheduling at diagnosis and at regular intervals (TRα-mediated bone sensitivity in RTHβ may accelerate bone resorption driven by elevated T4/T3 acting on TRα-expressing osteoclasts, while TRβ-mediated bone formation may be impaired in RTHα due to TRα-mediated hypothyroid skeletal effects), site-specific BMD documentation for lumbar spine and femoral neck, skeletal dysplasia assessment in RTHα where TRα-mediated bone effects produce hypothyroid skeletal phenotype (short stature, delayed bone age, macrocephaly in children), fracture risk stratification with FRAX where applicable, calcium and vitamin D supplementation documentation, pediatric bone age X-ray scheduling for children with RTHα where delayed bone age is a cardinal feature, growth velocity monitoring in pediatric RTH patients, orthopedic referral documentation for skeletal complications of RTHα, antiresorptive therapy documentation where warranted in adult RTHβ patients with established osteoporosis, and endocrine-skeletal interaction documentation for patients where gonadal function assessment adds an additional bone risk dimension — at a 2-minute interval.
Genetic Variant Documentation Platform
Monitor the genetic and molecular documentation service — including THRB mutation identification and full variant documentation (specific amino acid change, exon location, predicted pathogenicity, ClinVar classification), THRA mutation documentation for RTHα patients with separate phenotype tracking, genetic test report storage with laboratory accreditation documentation, variant interpretation documentation with functional significance explanation for clinical use, family pedigree documentation with first-degree relative identification for cascade screening coordination, genetic counseling session records documenting inheritance pattern explanation, reproductive planning counseling documentation (each pregnancy carries 50% transmission risk in RTHβ), prenatal testing consultation documentation, cascade screening referral letters and follow-up tracking, de novo mutation documentation where neither parent is affected (relevant for severity assessment and recurrence risk counseling), genotype-phenotype correlation documentation relating specific THRB variants to clinical severity in the literature, and clinical genetics co-management visit records — at a 2-minute interval.
EHR Synchronization Endpoint
Monitor the EHR synchronization service at a 5-minute interval. RTH patients presenting to emergency departments, urgent care settings, cardiologists, or any specialty provider outside the managing endocrinology team are at risk of having their elevated TSH with high free T4/T3 misinterpreted as primary hyperthyroidism or TSHoma requiring antithyroid intervention — making immediate access to the RTH diagnosis, THRB/THRA genetic variant, treatment contraindication flag, and managing endocrinologist contact information the highest-priority EHR synchronization obligation for this condition.
Authentication Service
Monitor authentication at a 1-minute interval. Auth failures lock endocrinologists, cardiologists, and geneticists out of the TSH trending, heart rate documentation, and variant records simultaneously — and critically block the over-treatment contraindication flags that protect RTH patients from iatrogenic thyroid ablation.
SSL Certificates Across All Platform Domains
Monitor certificate expiry 30 days in advance. Certificate failures block access to the RTH biochemical record, treatment contraindication documentation, and genetic variant database that lifetime RTH management requires.
Alerting Strategy for RTH Care Tech Platforms
Immediate clinical escalation (24/7): TSH and thyroid hormone monitoring platform, over-treatment risk monitoring platform, cardiac monitoring platform, and authentication service. These affect real-time disease activity assessment, iatrogenic harm prevention, tachycardia management, and the treatment contraindication access that patient safety in RTH requires.
Immediate clinical operations escalation: Genetic variant documentation platform. Access failures interrupt the variant records and cascade screening documentation that family management in this autosomal dominant disorder requires.
Scheduled escalation: Neurodevelopmental assessment platform and bone density monitoring platform. Access failures interrupt the ADHD management documentation and skeletal surveillance that symptomatic RTH management requires.
Business-hours engineering escalation: EHR synchronization. Investigate within one business hour — with highest priority for failures affecting the treatment contraindication flag and RTH diagnosis documentation accessible to emergency and urgent care providers.
Advance warning: SSL certificate expiry, 30 days in advance.
Status Page as a Clinical Safety Signal
Patients with thyroid hormone resistance syndrome — and their family members undergoing cascade genetic screening — need immediate platform status awareness when digital tools are unavailable. A published status page allows patients and care teams to distinguish a platform incident from connectivity problems and to ensure that the manual paper-based contraindication flag and genetic documentation remain available at emergency presentations when the digital platform is confirmed unavailable.
Publish the status page URL in patient care binders with particular emphasis on the treatment contraindication wallet card, endocrinology clinic coordination resources, cardiology co-management contacts, pediatric neurology and educational support teams, and RTH patient advocacy community resources where patients managing this rare genetic disorder seek peer information.
The Business Case: Over-Treatment Prevention, Cardiac Safety, and Genetic Surveillance
RTH specialty programs face significant exposure from TSH and thyroid hormone monitoring platform failures that interrupt the biochemical surveillance required to distinguish the RTHβ set-point from over-treatment — a distinction where falling free T4/T3 with "normalizing" TSH that superficially resembles biochemical improvement actually represents the clinical hypothyroidism that treatment contraindication documentation must prevent by ensuring all providers understand that the elevated-TSH-with-high-free-T4/T3 is the patient's required homeostatic equilibrium rather than a pathological finding to be corrected; from over-treatment risk monitoring platform failures that interrupt the contraindication flag accessibility that protects RTH patients from the antithyroid drug prescribing, radioiodine administration, or thyroidectomy scheduling that an unfamiliar provider encountering the paradoxical biochemistry at an emergency or urgent care presentation might initiate without the platform-documented RTH diagnosis and treatment constraint information that prevents this catastrophic therapeutic error; from cardiac monitoring platform failures that interrupt the heart rate trending and beta-blocker titration documentation that symptomatic tachycardia management in RTHβ requires across the cardiologist-endocrinologist co-management team that must coordinate tachycardia treatment without compromising the thyroid hormone levels that TRβ-resistant tissues need; from genetic variant documentation failures that interrupt the THRB or THRA mutation records that serve simultaneously as the definitive diagnostic reference, the inheritance pattern documentation for reproductive counseling, the cascade screening foundation for at-risk relatives, and the genotype-phenotype correlation record that informs clinical severity assessment and management personalization; from neurodevelopmental assessment platform failures that interrupt the ADHD symptom tracking and cognitive function documentation that pediatric RTH management requires across the school years where attentional and behavioral manifestations of TRα-mediated neurological sensitivity to elevated thyroid hormone most significantly impact educational and social outcomes; from bone density monitoring failures that interrupt the skeletal surveillance that TRα-mediated bone effects in RTHβ and the hypothyroid skeletal phenotype of RTHα require across the pediatric growth years where bone age assessment and growth velocity monitoring are critical management parameters and the adult years where bone density preservation requires documented surveillance; and from EHR synchronization failures that block emergency providers from accessing the diagnosis and treatment contraindication documentation that is uniquely critical in RTH because the biochemical fingerprint of this rare genetic disorder is indistinguishable from a pituitary tumor requiring surgery and from a thyroid disease requiring ablation — and only the platform-documented genetic diagnosis prevents the interventions that would harm rather than help the RTH patient.
External monitoring from Vigilmon provides the documented, independent availability record that RTH program directors can present to endocrinology department leadership, clinical genetics services, pediatric neurology, and institutional risk management as evidence that the program's digital infrastructure supports the continuous biochemical surveillance, treatment contraindication protection, cardiac monitoring, genetic documentation, and neurodevelopmental assessment that comprehensive thyroid hormone resistance syndrome management requires.
Vigilmon Setup for RTH Care Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | TSH and thyroid hormone monitoring platform | 1 min | PagerDuty (immediate, 24/7) | | Over-treatment risk monitoring platform | 1 min | PagerDuty (immediate, 24/7) | | Cardiac monitoring platform | 1 min | PagerDuty (immediate, 24/7) | | Auth service | 1 min | PagerDuty (immediate) | | Genetic variant documentation platform | 2 min | Slack (immediate) | | Neurodevelopmental assessment platform | 2 min | Slack (scheduled escalation) | | Bone density monitoring platform | 2 min | Slack (scheduled escalation) | | EHR synchronization endpoint | 5 min | Slack (business hours) + PagerDuty for contraindication flag and RTH diagnosis access | | SSL: all platform domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add the TSH and thyroid hormone monitoring platform at a 1-minute interval with immediate 24/7 PagerDuty alerting — biochemical set-point documentation is the primary management reference
- Add the over-treatment risk monitoring platform with immediate escalation — treatment contraindication flags are the most critical safety records in RTH
- Add cardiac monitoring with immediate escalation — tachycardia management is the primary symptomatic treatment obligation
- Add genetic variant documentation with immediate escalation — THRB/THRA variant records are lifetime clinical references for patients and families
- Add neurodevelopmental assessment platform with scheduled escalation — ADHD and cognitive monitoring guide pediatric management
- Add bone density monitoring with scheduled escalation — TRα-mediated skeletal effects require documented surveillance
- Add authentication and EHR synchronization — configure EHR to escalate immediately for contraindication flag and RTH diagnosis access at emergency and urgent care presentations
- Enable SSL monitoring across all patient-facing and clinician-facing domains
- Publish the automatic status page URL in patient care binders, cardiology co-management contacts, pediatric neurology resources, and RTH patient advocacy community channels
Conclusion
RTH care tech platforms hold the clinical monitoring infrastructure that makes safe, comprehensive management possible across the endocrine, genetic, cardiac, neurodevelopmental, and skeletal dimensions of this rare receptor-level thyroid hormone disorder — TSH and thyroid hormone monitoring platforms providing the biochemical set-point documentation that establishes the patient's required RTHβ equilibrium, serial surveillance distinguishing the set-point from over-treatment, SHBG measurement as a hepatic TRβ-sensitivity marker, thyroid antibody testing to exclude co-occurring autoimmune disease, goiter size monitoring, and the thyroid function interpretation framework that distinguishes adequate homeostasis from the clinical hypothyroidism that over-treatment produces in the TRβ-resistant patient who requires elevated circulating hormone levels to achieve adequate TRβ-mediated tissue function, over-treatment risk monitoring platforms providing the antithyroid drug and radioiodine contraindication flags, thyroidectomy contraindication documentation, TSH suppression contraindication alerting, emergency provider education documentation, and the active patient safety infrastructure that ensures every provider who encounters the paradoxical RTH biochemistry at any clinical encounter — planned or emergent, specialty or primary care — immediately accesses the genetic diagnosis and treatment constraint information that prevents the iatrogenic catastrophe of ablating the thyroid gland in a patient whose paradoxical TSH elevation reflects receptor-level resistance rather than a secreting pituitary tumor, cardiac monitoring platforms providing the resting heart rate trending, beta-blocker titration documentation, Holter monitoring scheduling, exercise tolerance assessment, echocardiogram structural evaluation, and cardiology co-management coordination that the tachycardia and palpitation management dimension of RTHβ requires in patients where TRα-mediated cardiac sensitivity to elevated thyroid hormone levels produces the most disabling symptoms of the condition and where adequate heart rate control through selective beta-1 blockade must be achieved without reducing the thyroid hormone levels that TRβ-resistant tissues require for adequate function, genetic variant documentation platforms providing the THRB or THRA mutation identification, ClinVar pathogenicity classification, family pedigree documentation, cascade screening coordination, reproductive counseling records, and the definitive diagnostic reference that serves as the clinical foundation for all future thyroid function interpretation in the patient and all at-risk relatives across the decades of family-level management that autosomal dominant RTHβ inheritance requires, neurodevelopmental assessment platforms providing the ADHD symptom quantification, cognitive function documentation, educational accommodation planning, stimulant therapy decision records, speech and language assessment in RTHα, behavioral intervention documentation, and pediatric-to-adult transition planning that the neurological dimension of thyroid hormone resistance requires in patients where TRα-mediated brain sensitivity to elevated hormone levels or TRα-mediated neurological hypothyroidism in RTHα produces attention, cognitive, and developmental challenges that span the school years and require coordinated documentation between endocrinology, neurology, and educational services, and bone density monitoring platforms providing the DEXA scheduling, BMD documentation, bone age X-ray scheduling in pediatric RTHα patients, growth velocity monitoring, fracture risk stratification, and skeletal complication documentation that the TRα-mediated bone effects of thyroid hormone resistance require across both the pediatric years where bone age and growth assessment guide management and the adult years where cortical bone density surveillance detects the accelerated resorption that sustained thyroid hormone elevation may drive through osteoclastic TRα signaling. Their availability is a prerequisite for the biochemical homeostasis preservation, iatrogenic harm prevention, cardiac symptom management, genetic family management, neurodevelopmental support, and bone density surveillance that patients with thyroid hormone resistance syndrome deserve across a lifetime condition where platform downtime creates simultaneous gaps in set-point documentation, contraindication flag accessibility, heart rate trending, variant record access, and developmental assessment in patients whose safety depends not only on adequate monitoring but on the treatment contraindication information that must be instantly accessible to every provider who might otherwise treat the paradoxical biochemistry as a pathology to be corrected rather than a genetic adaptation to be preserved.
External monitoring from Vigilmon provides the independent, outside-in availability view that RTH program directors and health system IT teams need to catch platform failures before they affect biochemical surveillance continuity, treatment contraindication protection, cardiac monitoring, or genetic documentation — with the documented incident record that endocrinology leadership, clinical genetics services, pediatric neurology, and institutional risk management accept as evidence of operational maturity in a program managing a rare genetic disorder where the consequences of platform downtime extend beyond data loss to the active patient safety risk of providers encountering the biochemistry without the diagnostic context that only the platform record provides.
Start monitoring your Thyroid Hormone Resistance Syndrome care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and PagerDuty integration. No agent required. No credit card.
Tags: #monitoring #ThyroidHormoneResistance #RTH #RTHbeta #RTHalpha #THRB #THRA #thyroidHormoneReceptor #TSH #freeT4 #freeT3 #centralHyperthyroidism #SHBG #goiter #tachycardia #betaBlocker #ADHD #neurodevelopmental #boneDensity #geneticCounseling #cascadeScreening #autosomDominant #TRIAC #overtreatment #iatrogenicHarm #rareDisease #endocrinology #clinicalGenetics #healthtech #uptime #clinicaldocumentation #sre